Complications of traditional Chinese/herbal medicines (TCM)-a guide for perplexed oncologists and other cancer caregivers

被引:42
作者
Chiu, Joanne [1 ]
Yau, Thomas [1 ]
Epstein, Richard J. [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Hematol Oncol, Hong Kong, Hong Kong, Peoples R China
关键词
Complementary and alternative medicine; Drug toxicity; Cancer chemotherapy; Herbs; HEPATIC VENOOCCLUSIVE DISEASE; ARISTOLOCHIC ACID; HERBAL MEDICINE; ALTERNATIVE MEDICINE; PROSTATE-CANCER; GANODERMA-LUCIDUM; PC-SPES; NUTRITIONAL SUPPLEMENTS; PYRROLIZIDINE ALKALOIDS; METABOLIC-ACTIVATION;
D O I
10.1007/s00520-008-0526-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Cancer patients often seek complementary or alternative medicines to supplement or replace treatments prescribed by licensed medical practitioners. Traditional Chinese/herbal medicine (TCM) is a popular complementary intervention among cancer patients of Asian ethnicity, many of whom take it during their conventional treatment. Few of these patients inform their doctors, however, creating a risk of unexpected sequelae arising from either pharmacologic toxicity, unsuitable dosing, interactions with anti-cancer drugs or other medications, adulteration, or idiosyncratic reactions. If unrecognized, these problems may be misattributed to conventional treatment toxicity or disease progression, and remedial action may be inappropriate or delayed. The purpose of this review is to help oncologists recognize the common presentations of TCM-related problems in cancer patients-such as abnormal liver function tests, unexpectedly severe myelosuppression, hemostatic defects, renal functional impairment, or suspected drug interactions-and to teach strategies by which these problems can be anticipated, prevented, or managed. Through sensitive understanding of the reasons favoring TCM usage, oncologists can gain the trust and respect of their TCM-using patients while ensuring the safety and efficacy of conventional anticancer treatments.
引用
收藏
页码:231 / 240
页数:10
相关论文
共 113 条
[1]
Methods for causality assessment of adverse drug reactions - A systematic review [J].
Agbabiaka, Taofikat B. ;
Savovic, Jelena ;
Ernst, Edzard .
DRUG SAFETY, 2008, 31 (01) :21-37
[2]
When is a herb a drug? [J].
Aithal, GR .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (04) :391-393
[3]
Psychosocial support, treatment of metastatic disease and palliative care [J].
Ashby, MA ;
Kissane, DW ;
Beadle, GF ;
Rodger, A .
MEDICAL JOURNAL OF AUSTRALIA, 1996, 164 (01) :43-&
[4]
Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment [J].
Bajwa, RPS ;
Cant, AJ ;
Abinun, M ;
Flood, T ;
Hodges, S ;
Hale, JP ;
Skinner, R .
BONE MARROW TRANSPLANTATION, 2003, 31 (07) :591-597
[5]
Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C [J].
Batey, RG ;
Bensoussan, A ;
Fan, YY ;
Bollipo, S ;
Hossain, MA .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (03) :244-247
[6]
Trends in complementary/alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005 [J].
Boon H.S. ;
Olatunde F. ;
Zick S.M. .
BMC Women's Health, 7 (1)
[7]
Brazier Nicole C, 2003, Am J Ther, V10, P163, DOI 10.1097/00045391-200305000-00003
[9]
Complementary and alternative therapies for cancer [J].
Cassileth, BR ;
Deng, G .
ONCOLOGIST, 2004, 9 (01) :80-89
[10]
Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation [J].
Chalandon, Y ;
Roosnek, E ;
Mermillod, B ;
Newton, A ;
Ozsahin, H ;
Wacker, P ;
Helg, C ;
Chapuis, B .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (05) :347-354